Sotagliflozin initiation

Phase 2Small molecule

Sotagliflozin initiation is one of 51 small molecule programs targeting Type 1 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes MellitusNot yet recruiting

Type 1 Diabetes MellitusPhase 2

Not yet recruiting

Competition

Competitive Landscape

67 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

2 2

Mounjaro

Eli Lilly

Approved

1 3

Prevacid

Rocaltrol

Estrace

Brethine

Ozempic

Diamox

Cibinqo

Farxiga

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Not yet recruiting

Type 1 Diabetes Mellitus

NCT07325201

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report

Not yet recruiting·HHealthPartners Institute·Phase 2·NCT07325201·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sotagliflozin initiation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sotagliflozin initiation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sotagliflozin initiation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HealthPartners Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHealthPartners Institute

Sotagliflozin initiation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News